- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00537485
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chubu region, Japan
-
Hokkaido region, Japan
-
Kanto region, Japan
-
Kinki region, Japan
-
Kyushu region, Japan
-
Tohoku region, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)"
- Subject is 30 years < > 80 years at the time of informed consent
- Hoehn & Yahr stage 1- 3
- Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test
Exclusion Criteria:
- Subject has previously participated in a trial with SPM 962
- Subject is on L-dopa treatment for total of over 6 months at the time of informed consent
- Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline
- Subject has orthostatic hypotension
- Subject has a history of epilepsy, convulsion and other
- Subject has a complication of serious cardiac disorder/arrhythmia or has the history
- Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)
- Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec of QTc values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline
- Subject has congenital long QT syndrome
- Subject has serum potassium of less than 3.5 mEq/L at screening test.
- Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test
- Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test
- Subject has a history of allergy to topical medicine, e.g. transdermal patch
- Subject is pregnant, nursing, or is child bearing potential while the trial
- Subject is receiving therapy with prohibited drug specified in the study protocol
- Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant
- Subject has dementia
- Subject is unable to give consent
- Subject is participating in another trial of an investigational drug or done so within 12 weeks prior to the initial treatment
- Investigator judges that subject is inappropriate as a study subject with other reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
transdermal application, 1 time per day
|
Placebo Comparator: 2
|
transdermal application, 1 time per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3
Time Frame: baseline, end of maintenance period
|
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
baseline, end of maintenance period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3
Time Frame: baseline, end of maintenance period
|
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period
|
baseline, end of maintenance period
|
Mean Change in UPDRS Part 2 Sum Score
Time Frame: Baseline, every two weeks
|
Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Baseline, every two weeks
|
Efficacy Rate in UPDRS Part 2 Sum Score
Time Frame: Baseline, every two weeks
|
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
|
Baseline, every two weeks
|
UPDRS Part 3 Sum Score
Time Frame: Baseline, every two weeks
|
Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Baseline, every two weeks
|
Efficacy Rate in UPDRS Part 3 Sum Score
Time Frame: Baseline, every two weeks
|
Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.
|
Baseline, every two weeks
|
UPDRS Part 1 Sum Score
Time Frame: Baseline, every two weeks
|
MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing. UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Baseline, every two weeks
|
UPDRS Part 4 Sum Score
Time Frame: Baseline, every two weeks
|
Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing. UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Baseline, every two weeks
|
Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4
Time Frame: Baseline, every two weeks
|
Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4. UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement. |
Baseline, every two weeks
|
The Modified Hoehn and Yahr Stage
Time Frame: Baseline, end of maintenance period
|
Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period.
The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.
|
Baseline, end of maintenance period
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Katsuhisa Saito, New Product Evaluation and Development
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 243-07-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Parkinson's Disease
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Professor Lu Neurological ClinicUnknownEarly Onset Parkinson DiseaseTaiwan
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Boehringer IngelheimCompletedEarly Parkinson Disease (Early PD)United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
-
Pharma Two B Ltd.CompletedParkinson Disease | Early Parkinson's DiseaseUnited States, Canada, Germany, Spain
-
Peptron, Inc.Active, not recruitingEarly Parkinson's DiseaseKorea, Republic of
-
UCB Biopharma SRLActive, not recruitingEarly-stage Parkinson's DiseaseUnited States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
-
UCB PharmaCompletedEarly-Stage Parkinson's DiseaseUnited States, Canada
-
UCB PharmaCompletedEarly Stage Parkinson's DiseasePoland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
-
Ligand PharmaceuticalsCompletedEarly Stage Parkinson's DiseaseUnited States
Clinical Trials on SPM 962
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedParkinson Disease, IdiopathicGermany
-
Otsuka Pharmaceutical Co., Ltd.CompletedParkinson's DiseaseJapan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedParkinson's DiseaseJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedParkinson's DiseaseJapan